ConAgra’s Petition For Whole Grain/Diabetes Claim Draws Opposition
This article was originally published in The Tan Sheet
Executive Summary
Kellogg Co. disagrees with ConAgra’s petition to FDA for a qualified health claim linking whole grain consumption with reduced risk of type 2 diabetes. Other experts question ConAgra’s supporting evidence and maintain fiber content should be emphasized over whole grains in product labeling.
You may also be interested in...
FDA Speaks Loudly On Approved Claims Language In Post Foods Warning
Similar claims likely are made for products marketed by others firms of various sizes, but a single warning letter to a manufacturer the size of Post Food speaks louder than similar letters to numerous smaller companies.
FDA Speaks Loudly On Approved Claims Language In Post Foods Warning
Similar claims likely are made for products marketed by others firms of various sizes, but a single warning letter to a manufacturer the size of Post Food speaks louder than similar letters to numerous smaller companies.
In Brief
Zeller heads FDA tobacco center; FDA denies P&G diabetes claim; Meda depends on OTCs; Ocean Nutrition boosts DSM; Elcelyx innovates in financing round; FDA warns DMAA firm on GMP violations; probiotics get Canadian claim approval.